Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
M Trøseid, JR Arribas, L Assoumou, AR Holten… - Critical care, 2023 - Springer
Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no
placebo-controlled trials have focused specifically on severe/critical COVID, including …
placebo-controlled trials have focused specifically on severe/critical COVID, including …
Drug repurposing and observational studies: the case of antivirals for the treatment of COVID-19
MA Hernán, J Del Amo - Annals of Internal Medicine, 2023 - acpjournals.org
Remdesivir and molnupiravir were the only 2 repurposed antivirals that were approved for
emergency use during the COVID-19 pandemic. Both drugs received their emergency use …
emergency use during the COVID-19 pandemic. Both drugs received their emergency use …
[HTML][HTML] Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial
HK Viermyr, K Tonby, E Ponzi, S Trouillet-Assant… - …, 2025 - thelancet.com
Summary Background The Bari-SolidAct randomized controlled trial compared baricitinib
with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher …
with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher …
No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 …
ML Verburgh, M van der Valk, BJA Rijnders, P Reiss… - Aids, 2023 - journals.lww.com
In two Dutch observational cohorts of people with HIV, the use of TDF, ETR, or INSTIs was
not independently associated with either the risk of incident SARS-CoV-2 infection or severe …
not independently associated with either the risk of incident SARS-CoV-2 infection or severe …
The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network …
Objectives The aim of this network meta-analysis (NMA) was to assess whether participants
assigned to a placebo and standard of care (SoC) group had different major coronavirus …
assigned to a placebo and standard of care (SoC) group had different major coronavirus …
Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA)
F Artigues Serra, S Pinecki Socias, FJ Fanjul… - PloS one, 2024 - journals.plos.org
Introduction The impact of SARS-CoV-2 infection among people living with HIV (PLWH) has
been a matter of research. We evaluated the incidence and factors associated with SARS …
been a matter of research. We evaluated the incidence and factors associated with SARS …
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
A Hill, M Mirchandani - Journal of Antimicrobial Chemotherapy, 2023 - academic.oup.com
In regulatory evaluations, high-quality randomized controlled trials (RCTs) are considered
the gold standard for assessing the efficacy of medical interventions. However, during the …
the gold standard for assessing the efficacy of medical interventions. However, during the …
Baricitinib statistically significantly reduced COVID-19-related mortality: a systematic review and meta-analysis of five phase III randomized, blinded and placebo …
S Manoharan, L Ying Ying - Biology Methods and Protocols, 2024 - academic.oup.com
Background Due to high heterogeneity and risk of bias (RoB) found in previously published
meta-analysis, a concrete conclusion on the efficacy of baricitinib in reducing mortality in …
meta-analysis, a concrete conclusion on the efficacy of baricitinib in reducing mortality in …
[HTML][HTML] Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized …
CS Kow, DS Ramachandram… - The Canadian Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Background The pathophysiology of COVID-19 involves a signalling pathway based on the
Janus kinases (JAKs) and the signal transducer and activator of transcription (STAT) family …
Janus kinases (JAKs) and the signal transducer and activator of transcription (STAT) family …